Island Pharmaceuticals Secures U.S. Patent for COVID‑19 Treatment
Island Pharmaceuticals has received a U.S. patent for using Galidesivir to treat COVID‑1, extending its intellectual‑property protection through July 2042. TipRanks+1 The patent strengthens Island’s antiviral portfolio and supports Galidesivir’s potential as a broad‑spectrum antiviral, aligning with its plans to target other serious viral threats like the Marburg virus. 
Island Pharmaceuticals Secures U.S. Patent for COVID‑19 Treatment